Clinical Trials Logo
  1. Home
  2. Measles
  3. NCT01602094
  4. Details
NCT01602094 Clinical Trial

Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors

Measles Clinical Trial

Official title:
Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT01602094
Other study ID # TAI5501
Secondary ID
Status Not yet recruiting
Phase N/A
First received May 16, 2012
Last updated May 17, 2012
Start date July 2012
Est. completion date March 2013

Study information
Verified date May 2012
Source Queen Saovabha Memorial Institute
Contact Jaruboot Angsanakul, M.D.
Phone 662-252-0161-4
Email jaruboot@yahoo.com
Is FDA regulated No
Health authority Thailand: Ministry of Public Health
Study type Observational

Clinical Trial Summary

Prevalence of participants who have protective immunity to measles virus is less than ninety percent.

Predictor of adequate measles antibody levels include the following :

- History of measles infection

- History of complete measles primary immunization( 2 doses with at least 1 month interval after age of 9 months)

- History of measles exposure

Predictor of inadequate measles antibody levels include the following :

- Born outside Thailand

- History of staying outside Thailand for long time in childhood

- Living in the rural area for a long period in childhood

- Fail to participate school system on time

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 550
Est. completion date March 2013
Est. primary completion date January 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria:

- Age 18-30 years old

Exclusion Criteria:

- Last measles vaccination less than 10 years of age

- Immunocompromised host including congenital immune defect, splenectomy or splenic dysfunction, history of suspect HIV exposure, taking immunosuppressant

- Receiving blood or blood product within 3 months

- Receiving others vaccinations or immunoglobulins or any medication that possibly decrease immune response

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional

Related Conditions & MeSH terms

Locations
Country Name City State
Thailand Queen Saovabha Memorial Institute Bangkok

Sponsors (1)
Lead Sponsor Collaborator
Queen Saovabha Memorial Institute

Country where clinical trial is conducted

Thailand, 

See also
  Status Clinical Trial Phase
Completed NCT04183114 - Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study) Phase 2/Phase 3
Completed NCT00092430 - Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Phase 3
Completed NCT02196285 - Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella Phase 1
Completed NCT00313950 - Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Phase 4
Completed NCT00384397 - A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers Phase 3
Completed NCT00402831 - ProQuad® Intramuscular vs Subcutaneous Phase 3
Completed NCT00560755 - Safety Study of ProQuad® rHA in Infants (V221-037) Phase 3
Completed NCT01878435 - Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya N/A
Completed NCT01777529 - Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Phase 4
Terminated NCT00258726 - Immune Responses to Two Dose Varivax +/- MMR-II Phase 1/Phase 2
Completed NCT00109278 - A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED) Phase 2
Not yet recruiting NCT05771779 - Co-administration Study of OCV, TCV and MR Phase 3
Completed NCT02880865 - Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine Phase 4
Completed NCT01681992 - Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Phase 3
Completed NCT00751348 - Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Phase 3
Completed NCT01702428 - Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Phase 3
Completed NCT00969436 - Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Phase 3
Completed NCT00566527 - Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) Phase 3
Completed NCT00127010 - Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Phase 3
Completed NCT00388440 - Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Phase 4

External Links